Radioembolization in the Office-Based Lab

Abstract

Interventional procedures have been performed on an outpatient basis in the hospital setting for many years, although there has been a clear trend toward performing these procedures in an outpatient facility, such as an ambulatory surgery center or office-based lab. And while this trend initially began with dialysis interventions and then endovascular interventions, interventional oncology is starting to catch on. Radioembolization has routinely been performed in an outpatient setting, and has recently gained traction in office-based labs due to new reimbursement codes, which became available in 2017. This article will outline the safety and feasibility, including economic considerations and demonstrated growth, of performing radioembolization in an office-based lab.

Keywords

office-based lab - outpatient - radioembolization

Publikationsverlauf

Eingereicht: 01. Dezember 2020

Angenommen: 27. Januar 2021

Artikel online veröffentlicht:
29. April 2021

• References

• 1 Manashil GB, Thunstrom BS, Thorpe CD, Lipson SR. Outpatient transluminal angioplasty. Radiology 1983; 147 (01) 7-8
• 2 Arnold WP. Improvement in hemodialysis vascular access outcomes in a dedicated access center. Semin Dial 2000; 13 (06) 359-363
• 3 Jain KM, Munn J, Rummel M, Vaddineni S, Longton C. Future of vascular surgery is in the office. J Vasc Surg 2010; 51 (02) 509-513 , discussion 513–514
• 4 Jain K, Munn J, Rummel MC, Johnston D, Longton C. Office-based endovascular suite is safe for most procedures. J Vasc Surg 2014; 59 (01) 186-191
• 5 Aurshina A, Ostrozhynskyy Y, Alsheekh A. et al. Safety of vascular interventions performed in an office-based lab in patients with low/moderate procedural risk. J Vasc Surg 2020; S07415214 (20) 32154-32156
• 6 Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 2002; 13 (9, Pt 2): S223-S229
• 7 Aberle S, Kenkel D, Becker AS. et al. Outpatient yttrium-90 microsphere radioembolization: assessment of radiation safety and quantification of post-treatment adverse events causing hospitalization. Radiol Med (Torino) 2020; 125 (10) 971-980
• 8 Hickey RM, Maslowski JM, Aaltonen ET. et al. Yttrium-90 radioembolization in the office-based lab. J Vasc Interv Radiol 2020; 31 (09) 1442-1448
• 9 Sirtex Medical. Coding Guide: Pretreatment Mapping and Microspheres Administration Hospital Outpatient, ASC, OBIS and Physician Services. January 2019. Accessed February 20, 2021 at: https://www.sirtex.com/media/168654/2019-sirtex-coding-guide-final-approved-085-u-0119-0101019docx.pdf
• 10 Turley RS, Mi X, Qualls LG. et al. The effect of clinical care location on clinical outcomes after peripheral vascular intervention in Medicare beneficiaries. JACC Cardiovasc Interv 2017; 10 (11) 1161-1171
• 11 Schramm KM, DeWitt PE, Dybul S. et al. Recent trends in clinical setting and provider specialty for endovascular peripheral artery disease interventions for the Medicare population. J Vasc Interv Radiol 2020; 31 (04) 614-621.e2
• 12 Liu LB, Cedillo MA, Bishay V. et al. Patient experience and preference in transradial versus transfemoral access during transarterial radioembolization: a randomized single-center trial. J Vasc Interv Radiol 2019; 30 (03) 414-420
• 13 Allimant C, Kafrouni M, Delicque J. et al. Tumor targeting and three-dimensional voxel-based dosimetry to predict tumor response, toxicity, and survival after yttrium-90 resin microsphere radioembolization in hepatocellular carcinoma. J Vasc Interv Radiol 2018; 29 (12) 1662-1670.e4